Related Experiment Videos
[Current status and therapeutic strategy for hepatocellular carcinoma]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1990
Summary
Hepatocellular carcinoma (HCC) is rising in Japan, linked to Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections. Prophylaxis and early detection are key to reducing HCC rates.
Area of Science:
- Hepatology
- Virology
- Oncology
Context:
- Increasing incidence of hepatocellular carcinoma (HCC) in Japan.
- Rise in HBsAg-negative HCC patients with transfusion history.
- Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are implicated in liver disease.
Purpose:
- To investigate the role of HBV and HCV in HCC development in Japan.
- To explore the association between viral hepatitis markers and HCC.
- To propose strategies for HCC prevention and management.
Summary:
- At least 40% of Japanese HCC patients show HBV infection markers, with HBV DNA detected in 15% of HBsAg-negative cases.
- Approximately 70% of HBsAg-negative HCC patients in Japan are positive for anti-HCV antibodies.
- HBV and HCV are estimated to be responsible for 85% of HCC cases through liver cirrhosis development.
Impact:
- Highlights the significant contribution of HBV and HCV to HCC in Japan.
- Emphasizes the need for strategies including prophylaxis, cirrhosis prevention, and early HCC detection.
- Suggests that controlling HBV and HCV infections could lead to a substantial decrease in HCC incidence.